Search

Displaying results 2091 - 2100 of 4590 in total
  1. Drug

    Fosdenopterin

    go.drugbank.com/drugs/DB16628
    Approved

    [A230088] Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity. … In 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A.

  2. Drug

    Verteporfin

    go.drugbank.com/drugs/DB00460
    ApprovedInvestigational

    Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet

  3. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    [A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary

  4. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    On May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189].

  5. Drug

    Ulixertinib

    go.drugbank.com/drugs/DB13930
    Investigational

    Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity [A31474].

  6. Drug

    Londamocitinib

    go.drugbank.com/drugs/DB19190
    Investigational

    Londamocitinib is under investigation in clinical trial NCT06020014 (Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-severe Asthma Uncontrolled on Medium-high

  7. Drug

    SRN-101

    go.drugbank.com/drugs/DB33962
    Experimental

    SRN-101 is under investigation in clinical trial NCT07826949 (A Phase 1 Study of SRN-101 Administered Prior to Surgical Resection in Adults With Recurrent High-Grade Glioma.).

  8. Drug

    Vericiguat

    go.drugbank.com/drugs/DB15456
    ApprovedInvestigational

    [L31178] Vericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure. … , sGC enzymes are intracellular enzymes found in vascular smooth muscle cells (amongst other cell types) that catalyze the synthesis of cyclic guanosine monophosphate (cGMP) in response to activation by

  9. Drug

    Motexafin lutetium

    go.drugbank.com/drugs/DB05296
    Investigational

    Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate ...

  10. Drug

    Imipramine

    go.drugbank.com/drugs/DB00458
    ApprovedInvestigational

    In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood.